- A restrictive approach to blood cell transfusions in patients undergoing cardiopulmonary bypass surgery led to fewer transfusions than a more liberal approach, without any increased risk of acute kidney injury.
- The results were consistent in patients with and without chronic kidney disease before surgery.
Newswise — Washington, DC (June 20, 2019) — In a recent clinical trial of higher risk patients undergoing cardiopulmonary bypass surgery, a restrictive approach to blood cell transfusions resulted in fewer transfusions without putting patients at increased risk of acute kidney injury. The findings appear in an upcoming issue of JASN.
Reducing blood cell transfusions during surgery could prevent transfusion-related adverse effects, conserve the blood supply, and reduce healthcare costs, but it might also have negative effects on the kidneys due to a variety of mechanisms. To investigate, Amit X. Garg, MD, PhD, (Lawson Health Research Institute in Ontario) and his colleagues conducted a randomized clinical trial called TRICS-III. The trial included 4531 higher risk patients undergoing cardiopulmonary bypass surgery across 73 centers in 19 countries. Patients were randomized to a restrictive transfusion approach (transfuse only if hemoglobin is below 7.5 g/dL) or a more liberal approach (transfuse if hemoglobin is less than 9.5 g/dL).
Patients in the restrictive transfusion group received 38% fewer transfusions than patients in the liberal group (1.8 vs. 2.9 transfusions, on average, respectively), and the approaches were equally safe with respect to risk of acute kidney injury. Risk were similar between patients with and without chronic kidney disease before surgery.
“With over 20 million cardiac surgeries performed worldwide each year—with it being one of the more common reasons for using blood in the hospital and an average of about 3 units of red blood cells used per patient—this suggests that approximately 20 million units of blood transfusions could be avoided each year without influencing the chance that a patient will develop post-operative kidney injury,” said Dr. Garg.
In an accompanying editorial, Iain Macdougall, MD, PhD (King’s College Hospital, in the UK) and Toby Richards, MD (University of Western Australia) noted that the study represents one of the largest trials assessing acute kidney injury ever performed, but they pointed to several limitations.
Study co-authors include Neal Badner, MD; Sean M. Bagshaw, MD, MSc; Meaghan S. Cuerden, MSc; Dean A. Fergusson, PhD; Alexander J. Gregory, MD; Judith Hall, MSc; Gregory M.T. Hare, MD, PhD; Boris Khanykin, MD; Shay McGuinness, MBBS MD; Chirag R. Parikh, MD, PhD; Pavel S. Roshanov, MD, MSc; Nadine Shehata, MD, MSc; Jessica M. Sontrop, PhD; Summer Syed, MD, MSc; George I. Tagarakis, MD; Kevin E. Thorpe, PhD; Subodh Verma, MD, PhD; Ron Wald, MD, MPH; Richard P. Whitlock, MD, PhD; and C. David Mazer, MD.
Disclosures: The authors reported no financial disclosures.
The article, entitled “Safety of a Restrictive versus Liberal Approach to Red Blood Cell Transfusion on the Outcome of AKI in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial,” will appear online at http://jasn.asnjournals.org/ on June 20, 2019, doi: 10.1681/ASN.2019010004.
The editorial, entitled “Restricting Red-Cell Transfusions in Cardiac Surgery: No Increase in Acute Kidney Injury,” will appear online at http://jasn.asnjournals.org/ on June 20, 2019.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 131 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.
# # #